摘要
目的探讨乌司他丁联合生长抑素治疗急性重症胰腺炎患者的临床疗效。方法选取2013年1月至2015年12月收治的100例急性重症胰腺炎患者作为研究对象,按随机数字表法将其分为对照组与观察组,每组50例。所有患者均给于常规对症治疗,同时对照组患者加用生长抑素,观察组患者在对照组基础上采用乌司他丁进行治疗。比较两组患者腹部不适缓解时间、肠功能恢复时间、淀粉酶恢复时间、住院时间、临床疗效、病死率、并发症发生情况。结果观察组患者腹部不适缓解时间、肠功能恢复时间、血尿淀粉酶恢复时间、住院时间均明显短于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者并发症发生率、病死率均明显低于对照组,差异均有统计学意义(均P<0.05)。结论在急性重症胰腺炎的临床治疗中,采用生长抑素联合乌司他丁治疗临床疗效显著,可有效改善患者的临床症状及体征,减少并发症发生,进而降低病死率。
Objective To investigate the clinical effect of ulinastatin combined with somatostatin in the treatment of patients with severe acute pancreatitis.Methods From January 2013 to December 2015,100 cases of patients with acute severe pancreatitis in our hospital as the research object,according to the random number table method is divided into the control group and the observation group,each group of 50 cases.All patients were given routine symptomatic treatment,while the control group was treated with somatostatin,patients in the observation group in the control group based on the use of ulinastatin treatment.Compared the two groups of patients with abdominal discomfort time,bowel function recovery time,amylase recovery time,hospital stay,clinical efficacy,mortality,complications. Results The observation group of patients with abdominal discomfort,ease time,intestinal function recovery time, hematuria amylase recovery time,hospitalization time were significantly shorter than the control group,the differences were statistically significant（P0.05）;patients in the observation group the total effective rate of treatment was significantly higher than the control group,the difference was statistically significant（P 0.05）;patients in the observation group complication rate and mortality rate were significantly lower than the control group,the differences were statistically significant（P〈0.05）.Conclusion In the clinical treatment of severe acute pancreatitis,with somatostatin combined with ulinastatin treatment,can effectively improve the clinical symptoms and signs of patients,reduce complications,and reduce the mortality rate.
出处
《中国药物经济学》
2017年第2期39-41,共3页
China Journal of Pharmaceutical Economics
